RHYTHM PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Increase (Decrease) in Inventories of $5.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $2.34M.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $3.09M, a 436.70% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $4.93M, a 1.67% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $2.45M, a 28.93% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $7.47M, a 26.12% decline from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was $10.12M, a 77.27% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was $5.71M, a 103.39% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $2.81M, a 25409.09% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.43M 10-Q · filed 2026-08-04 | $10.36M derived: sum of 3 quarters · filed 2026-08-04 | $12.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.09M 10-Q · filed 2026-05-05 | $8.01M derived: sum of 2 quarters · filed 2026-05-05 | $10.46M derived: sum of 3 quarters · filed 2026-05-05 | $9.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.38M derived: sum of 2 quarters · filed 2026-02-26 | $6.90M derived: sum of 3 quarters · filed 2026-08-04 | $7.47M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.97M derived: sum of 2 quarters · filed 2026-08-04 | $2.55M 10-Q · filed 2025-11-04 | $7.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$479.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $96.00K 10-Q · filed 2026-08-04 | $4.94M derived: sum of 3 quarters · filed 2026-08-04 | $6.84M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $575.00K 10-Q · filed 2026-05-05 | $5.42M derived: sum of 2 quarters · filed 2026-05-05 | $7.32M derived: sum of 3 quarters · filed 2026-05-05 | $10.81M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.75M derived: sum of 2 quarters · filed 2026-02-26 | $10.23M derived: sum of 3 quarters · filed 2026-02-26 | $10.12M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.39M derived: sum of 2 quarters · filed 2025-11-04 | $5.27M 10-Q · filed 2025-11-04 | $6.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.37M 10-Q · filed 2025-08-05 | $4.23M derived: sum of 3 quarters · filed 2026-02-26 | $5.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$117.00K 10-Q · filed 2025-05-07 | $745.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.33M derived: sum of 3 quarters · filed 2026-02-26 | $3.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $862.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.45M derived: sum of 2 quarters · filed 2026-02-26 | $3.14M derived: sum of 3 quarters · filed 2026-02-26 | $5.71M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.27M derived: sum of 2 quarters · filed 2024-11-06 | $4.84M 10-Q · filed 2024-11-06 | $6.08M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $690.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.26M 10-Q · filed 2024-08-06 | $4.49M derived: sum of 3 quarters · filed 2025-02-28 | $4.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.57M 10-Q · filed 2024-05-07 | $3.80M derived: sum of 2 quarters · filed 2025-02-28 | $3.80M derived: sum of 3 quarters · filed 2025-02-28 | |
| 2022-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $1.23M derived: sum of 2 quarters · filed 2025-02-28 | $2.81M 10-K · filed 2025-02-28 | |
| 2022-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.57M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $1.58M 10-Q · filed 2023-08-01 | |||
| 2021-12-31 | $11.00K 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |